Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1997 1
1999 1
2000 1
2001 1
2002 1
2004 1
2005 1
2006 2
2007 4
2008 5
2009 5
2010 5
2011 7
2012 4
2013 3
2014 4
2015 2
2016 7
2017 3
2018 4
2019 2
2020 2
2021 2
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Warfarin pharmacogenetics.
Limdi NA, Veenstra DL. Limdi NA, et al. Pharmacotherapy. 2008 Sep;28(9):1084-97. doi: 10.1592/phco.28.9.1084. Pharmacotherapy. 2008. PMID: 18752379 Free PMC article. Review.
We review the evidence of the influence of the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the vitamin K epoxide reductase complex 1 gene, VKORC1, on warfarin response and discuss the implications of current knowledge for clinical practice. …
We review the evidence of the influence of the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the vitamin K epoxide re …
Genotype-guided warfarin therapy: current status.
Tavares LC, Marcatto LR, Santos PCJL. Tavares LC, et al. Pharmacogenomics. 2018 May;19(7):667-685. doi: 10.2217/pgs-2017-0207. Epub 2018 Apr 27. Pharmacogenomics. 2018. PMID: 29701078 Review.
Warfarin pharmacogenomics has been an extensively studied field in the last decades as it is focused on personalized therapy to overcome the wide interpatient warfarin response variability and decrease the risk of side effects. ...
Warfarin pharmacogenomics has been an extensively studied field in the last decades as it is focused on personalized therapy to overcome the …
The pharmacogenetics of the response to warfarin in Chinese.
Lam MP, Cheung BM. Lam MP, et al. Br J Clin Pharmacol. 2012 Mar;73(3):340-7. doi: 10.1111/j.1365-2125.2011.04097.x. Br J Clin Pharmacol. 2012. PMID: 22023024 Free PMC article. Review.
The VKORC1 genotype is an important determinant of response to warfarin in Chinese, but some genetic variants found in other ethnic groups that have a large effect on warfarin response and dosing are not commonly found in Chinese. Therefore, it is important to recog …
The VKORC1 genotype is an important determinant of response to warfarin in Chinese, but some genetic variants found in other ethnic groups t …
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Hirata TDC, Dagli-Hernandez C, Genvigir FDV, Lauschke VM, Zhou Y, Hirata MH, Hirata RDC. Hirata TDC, et al. Mol Diagn Ther. 2021 Nov;25(6):735-755. doi: 10.1007/s40291-021-00549-z. Epub 2021 Aug 6. Mol Diagn Ther. 2021. PMID: 34357562 Review.
Multiple Brazilian studies assessed the impact of pharmacokinetic (PK) and pharmacodynamic (PD) gene variants on warfarin response. The reduced function alleles CYP2C9*2 and CYP2C9*3, and VKORC1 rs9923231 (c.-1639G>A) are associated with increased sensitivity to …
Multiple Brazilian studies assessed the impact of pharmacokinetic (PK) and pharmacodynamic (PD) gene variants on warfarin response …
Pharmacogenetics and oral antithrombotic drugs.
Baker WL, Johnson SG. Baker WL, et al. Curr Opin Pharmacol. 2016 Apr;27:38-42. doi: 10.1016/j.coph.2016.01.008. Epub 2016 Feb 15. Curr Opin Pharmacol. 2016. PMID: 26878737 Review.
Genetic variants in CYP2C9 and VKORC1 have been identified and shown to explain some of the variability in warfarin response. Prospective trials suggest that incorporation of genotype results in faster time to therapeutic range than without; however, whether these i …
Genetic variants in CYP2C9 and VKORC1 have been identified and shown to explain some of the variability in warfarin response. …
Association between apolipoprotein E genotype and warfarin response during initial anticoagulation.
He S, Zhang H, Cao Y, Nian F, Chen H, Chen W, Auchoybur ML, Yin L, Tao Z, Tang S, Chen X. He S, et al. Biomed Pharmacother. 2018 May;101:251-256. doi: 10.1016/j.biopha.2018.02.095. Epub 2018 Feb 27. Biomed Pharmacother. 2018. PMID: 29494962
Apolipoprotein E (APOE) genotypes are associated with warfarin dose requirements in various populations. Whether APOE genotypes mediate the warfarin response is unknown. The aim of this study was to evaluate the genetic contributions of different APOE genotypes to t …
Apolipoprotein E (APOE) genotypes are associated with warfarin dose requirements in various populations. Whether APOE genotypes mediate the …
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.
Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Jorgensen AL, et al. PLoS One. 2012;7(8):e44064. doi: 10.1371/journal.pone.0044064. Epub 2012 Aug 29. PLoS One. 2012. PMID: 22952875 Free PMC article. Review.
Navigating the literature to determine how genotype will influence warfarin response in a particular patient is difficult, due to significant variation in patient ethnicity, outcomes investigated, study design, and methodological rigor. ...Notably, there was signifi …
Navigating the literature to determine how genotype will influence warfarin response in a particular patient is difficult, due …
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.
Cavallari LH, Shin J, Perera MA. Cavallari LH, et al. Pharmacotherapy. 2011 Dec;31(12):1192-207. doi: 10.1592/phco.31.12.1192. Pharmacotherapy. 2011. PMID: 22122181 Free PMC article. Review.
Over the past decade, there has been substantial progress in our understanding of genetic contributions to variable warfarin response, particularly with regard to warfarin dose requirements. ...The CYP4F2 gene influences vitamin K availability and makes minor contri …
Over the past decade, there has been substantial progress in our understanding of genetic contributions to variable warfarin respo …
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
Cross B, Turner RM, Zhang JE, Pirmohamed M. Cross B, et al. Pharmacogenomics J. 2024 Mar 5;24(2):7. doi: 10.1038/s41397-024-00329-y. Pharmacogenomics J. 2024. PMID: 38443337 Free PMC article. Review.
Validated variants in VKORC1, CYP2C9 and CYP4F2 constitute biomarkers for differential warfarin response and genotype-informed warfarin dosing has been shown to reduce adverse clinical events. ...
Validated variants in VKORC1, CYP2C9 and CYP4F2 constitute biomarkers for differential warfarin response and genotype-informed …
Is personalized medicine a dream or a reality?
Morse BL, Kim RB. Morse BL, et al. Crit Rev Clin Lab Sci. 2015 Feb;52(1):1-11. doi: 10.3109/10408363.2014.950407. Epub 2014 Sep 2. Crit Rev Clin Lab Sci. 2015. PMID: 25181036
We will outline the importance of understanding all of the variables that mediate warfarin response as the prerequisite to successful utilization of genotype-guided warfarin therapy. ...
We will outline the importance of understanding all of the variables that mediate warfarin response as the prerequisite to suc …
65 results